Noa Biran, MD

Articles

Dr. Biran on Post-ASCT Consolidation in Multiple Myeloma

February 1st 2020

Noa Biran, MD, physician, discusses elotuzumab (Empliciti) as post-autologous stem cell transplant consolidation in patients with high-risk myeloma.

Dr. Biran on 2-Year Update of Immunotherapy Triplet in High-Risk Multiple Myeloma

December 8th 2019

Noa Biran, MD, physician, John Theurer Cancer Center, discusses the 2-year update of a phase II trial of pembrolizumab (Keytruda), lenalidomide (Revlimid), and dexamethasone as post-autologous stem cell transplant consolidation in patients with high-risk multiple myeloma.

Dr. Biran on New Agents and Combos in Relapsed Multiple Myeloma

July 11th 2019

Noa Biran, MD, discusses new agents and combinations being studied for relapsed multiple myeloma.

Dr. Biran Discusses Treatment Discontinuation in Myeloma

July 13th 2018

Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses treatment discontinuation in multiple myeloma.

Dr. Biran on Patient-Reported Outcomes Following Transplant in Multiple Myeloma

June 14th 2018

Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses patient-reported outcomes following autologous stem cell transplantation in multiple myeloma.

Dr. Biran Discusses Doublets Versus Triplets in Myeloma

March 30th 2018

Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses doublets versus triplets in the treatment of patients with multiple myeloma.

Clinical Decision Making in Multiple Myeloma for the Transplant-Eligible Patient–Upfront Transplant Versus Maintenance Therapy

December 31st 2015

With the development of novel therapies, the role and optimal timing of autologous stem cell transplant for the treatment of multiple myeloma have come into question.

Monoclonal Antibody-Directed Therapies for the Management of Multiple Myeloma

May 11th 2015

Several monoclonal antibodies with multiple myeloma cell antigen or bone marrow targets have exhibited strong antimyeloma activity and may become potential therapeutic agents.

x